- Otonomy (NASDAQ:OTIC -0.8%) commences a Phase 2 clinical trial assessing a single administration of OTIPRIO (ciprofloxacin otic suspension) for the treatment of pediatric patients with acute otitis media (ear infection) with tympanostomy tubes (AOMT). The aim is to determine the optimal dose for further development for the indication.
- The company completed an earlier Phase 2 that showed the feasibility of administering OTIPRIO (formerly AuriPro) in pediatric patients with AOMT in an office setting.
- OTIPRIO is a sustained-exposure formulation of the antibiotic ciprofloxacin administered into the inner ear.
- The FDA approved OTIPRIO in December 2015 for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube replacement.